Results 91 to 100 of about 346 (112)
What is the pipeline for future medications for obesity? [PDF]
Int J Obes (Lond)Melson E +3 more
europepmc +1 more source
Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe. [PDF]
Front Endocrinol (Lausanne)Chondrogianni ME +9 more
europepmc +1 more source
A glossary of commodities, weights and measures found in the sixteenth-century Bristol customs account [PDF]
, 2009 Flavin, S, Jones, E T
core
Some of the next articles are maybe not open access.
Related searches:
Related searches:
American Journal of Physiology - Endocrinology and Metabolism, 2016
This study aims to elucidate the mechanism behind the potent weight loss induced by dual amylin and calcitonin receptor agonists (DACRA) through comparison of the novel DACRA KBP-088 with the amylinomimetic davalintide with regard to in vitro receptor pharmacology and in vivo efficacy on food intake and body weight. KBP-088 and davalintide were tested
Morten Asser Karsdal, Kim Henriksen
exaly +3 more sources
This study aims to elucidate the mechanism behind the potent weight loss induced by dual amylin and calcitonin receptor agonists (DACRA) through comparison of the novel DACRA KBP-088 with the amylinomimetic davalintide with regard to in vitro receptor pharmacology and in vivo efficacy on food intake and body weight. KBP-088 and davalintide were tested
Morten Asser Karsdal, Kim Henriksen
exaly +3 more sources
International Journal of Obesity
Dual amylin and calcitonin receptor agonists (DACRAs) are therapeutic candidates in the treatment of obesity with beneficial effects on weight loss superior to suppression of food intake. Hence, suggesting effects on energy expenditure by possibly targeting mitochondria in metabolically active tissue.Male rats with HFD-induced obesity received a DACRA,
Anna Thorsø Larsen +1 more
exaly +4 more sources
Dual amylin and calcitonin receptor agonists (DACRAs) are therapeutic candidates in the treatment of obesity with beneficial effects on weight loss superior to suppression of food intake. Hence, suggesting effects on energy expenditure by possibly targeting mitochondria in metabolically active tissue.Male rats with HFD-induced obesity received a DACRA,
Anna Thorsø Larsen +1 more
exaly +4 more sources
2016-P: High Dose DACRA Treatment Improves Glucose Homeostasis, without Additional Weight Loss
Diabetes, 2019KBP is a Dual Amylin and Calcitonin Receptor Agonist (DACRA). DACRAs have shown efficacy on weight loss and glucose control in rats. However, it is unclear whether the maximum effect has been reached. High Fat Diet (HFD, 60% fat) fed male Sprague-Dawley rats entered a dose escalation regimen ending at 5 (normal dose), 50 or 500 µg/kg daily KBP (n=10 ...
NINA SONNE +4 more
openaire +1 more source
1995-P: Optimization of DACRA Dosing Frequency—The Balance between Efficacy and Tolerability
Diabetes, 2019Potent dual amylin and calcitonin receptor agonists (DACRAs) are novel candidates for treatment of T2D and obesity due to their beneficial effects on body weight, blood glucose and insulin sensitivity. Notably, DACRAs activate the receptors for a prolonged time period resulting in metabolic effects superior to those of amylin.
ANNA T. LARSEN +4 more
openaire +1 more source